Currency Market Signals Doubt That Iran Deal Lowers Israel’s Risk
The shekel’s reaction to the agreement with Iran became the clearest sign of how investors interpreted the deal on the trading day. In early morning trading, the Israeli currency jumped to 2.88 per dollar and strengthened against the euro from 3.38 to 3.34, initially extending a pattern seen over the past two years, where easing geopolitical risk quickly lifts the shekel. Since the war began, the local currency has served as an especially sensitive barometer of investor risk appetite, at times even more than the Tel Aviv stock market.
As trading progressed, that picture reversed. The shekel erased all of its gains and weakened against the euro, while the Tel Aviv exchange moved from modest declines to broad selling in bank stocks, insurance companies, and defense firms. In effect, both the foreign exchange market and equities were sending the same message, investors are not convinced the agreement truly reduces Israel’s long-term risk.
The market’s skepticism appears tied to the content of the deal and the questions it leaves unanswered. From investors’ perspective, an arrangement that buys only a few weeks or months, without resolving the wider Iran problem, may be seen as a temporary pause rather than a real solution. If the issue returns to center stage in 60 days, the risk premium has not disappeared, only been delayed.
Another concern is the relationship between Washington and Jerusalem. Traders are increasingly sensitive to signs of tension between the Trump administration and the Netanyahu government, and to whether the United States will remain deeply engaged in the region. For some investors, the danger is not only Iran itself, but also the possibility that Israel will face it with more limited American backing.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.